Analyst Cory Jubinville, PhD of LifeSci Capital maintained a Buy rating on Tarsus Pharmaceuticals (TARS – Research Report), boosting the price target to $85.00.
Cory Jubinville, PhD has given his Buy rating due to a combination of factors that highlight Tarsus Pharmaceuticals’ strong performance and future potential. The company has consistently surpassed earnings expectations, with significant growth in Xdemvy revenues, reaching $66.4 million in Q4 2024 and $180.1 million for the full year. This growth is driven by an increase in prescription volumes and a broad prescriber base, supported by extensive coverage across commercial and Medicare plans.
Jubinville’s analysis suggests that Tarsus could achieve revenues exceeding $350 million in 2025, a target he considers conservative given the current trends. The stock’s recent weakness, despite strong earnings, presents a buying opportunity, as the momentum from the Xdemvy launch continues into 2025. The expanded coverage and positive feedback from prescribers are expected to sustain growth, making Tarsus an attractive investment prospect.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $73.00 price target.